Palmitoylethanolamide

Product Description

Taking PEA to supplement the body’s shortage is may be beneficial if you have chronic and neuropathic pain and inflammation, as has been demonstrated in clinical trials. These include peripheral neuropathies such as diabetic neuropathy, chemotherapy-induced peripheral neuropathy, carpal tunnel syndrome, sciatic pain, osteoarthritis, low-back pain, failed back surgery syndrome, dental pains, neuropathic pain in stroke and multiple sclerosis, chronic regional pain syndrome, chronic pelvic pain, postherpetic neuralgia, and vaginal pains.

Wuxi Further Pharmaceutical Co., Ltd

  • Country/Region:
    China
  • On CPHI since:
    2023
Company types
CMO/CDMO
Specifications
  • CAS Registry Number
    544-31-0
  • Details
    Palmitoylethanolamide powder Supplier PEA Ultramicronized CAS 544-31-0 Purity99%, Anti-inflammatory Dietary supplement
  • Selling Points
    Palmitoylethanolamide(PEA) 's Uses and Benefits:1)Pain management:As a dietary supplement for reduce pain, PEA has analgesic (pain-relieving) properties and has been studied for its potential use in managing chronic pain conditions.  2)Anti-inflammatory effects:PEA has been shown to have anti-inflammatory properties. It can inhibit the release of pro-inflammatory molecules and reduce the activation of immune cells involved in inflammation. PEA's anti-inflammatory effects may contribute to its analgesic properties.3) Neuroprotective effects: PEA has been investigated for its potential neuroprotective effects. It has been shown to protect neurons from damage caused by inflammation, oxidative stress, and other harmful processes. This suggests that PEA may have potential applications in neurodegenerative conditions and brain injuries.4)Mood and anxiety modulation:PEA has been studied for its potential effects on mood and anxiety disorders. It may exert its effects by...
  • Model
    Palmitoylethanolamide micronized
  • Supplied from
    China
  • Measured In
    Barrel

Wuxi Further Pharmaceutical Co., Ltd

  • Country/Region:
    China
  • On CPHI since:
    2023
Company types
CMO/CDMO